Affordable Access

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

Authors
  • Tack, Jan; 15849;
  • Stanghellini, Vincenzo;
  • Mearin, Fermin;
  • Yiannakou, Yan;
  • Layer, Peter;
  • Coffin, Benoit;
  • Simren, Magnus;
  • Mackinnon, Jonathan;
  • Wiseman, Gwen;
  • Marciniak, Anne;
  • Le, Sidanier;
  • Van, der Voort;
  • Von, Arnim;
  • De, Angelis;
  • Di, Mario;
  • Di, Stefano;
Publication Date
May 07, 2019
Source
Lirias
Keywords
License
Unknown
External links

Abstract

BACKGROUND: Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). METHODS: An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. RESULTS: Five hundred twenty-five patients were included, 60% (range: 43.1-78.8%) suffered from severe IBS-C. During follow-up 11.1-24.0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1.5-12.0 days and 41.1-90.4% took prescription drugs for IBS-C. 21.4-50.8% of employed patients took sick leave (mean: 11.6-64.1 days). The mean annual direct cost to the healthcare systems was €937.1- €2108.0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421.7-€2487.1. CONCLUSIONS: IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits. / status: published

Report this publication

Statistics

Seen <100 times